Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Why Everyone Should Be Screened for HCV and Treated If They Have It: Conversations Between Patient and Physician

This episode features a conversation between a patient, Shelley Rossell, and Norah Terrault, MD, MPH, who discuss the importance of universal HCV screening, the ease and benefits of DAA therapy, and how patients can be effective self-advocates for, during, and after treatment
Norah Terrault Headshot
Norah Terrault, MD, MPH
Released: May 3, 2022

In this episode, Norah Terrault, MD, MPH, and a patient who has been cured of hepatitis C virus (HCV) infection discuss the importance of universal HCV testing for all adults, as well as the ease of curative therapies and the benefits of living with improved liver function post cure.

This insightful discussion underscores how perceptions around HCV transmission risks and lack of symptoms serve as barriers to adequate screening and diagnosis, preventing curative treatment for many people with undiagnosed disease. The conversation also highlights the critical role of patient education and self-advocacy related to HCV infection, including what patients need to know and expect following cure.

Information on this Educational Activity

Faculty

Norah Terrault, MD, MPH

Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California

Norah Terrault, MD, MPH, has disclosed that she has received funds for research support from Gilead Sciences, GlaxoSmithKline, and Roche/Genentech.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Clinical Care Options (CCO) expert analysis by Prof Stefan Zeuzem on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings